Whether you are a healthcare professional, researcher, or student in the life sciences, this course will

July 2022 Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials "HTL0039732 is a novel EP4 antagonist with potential to treat a wide range of cancers biopharmaceutical company and world-leader in GPCR1-focused structure-based drug design (SBDD) and development, and Cancer Research UK, the world’s largest private funder of cancer research, today announce the signing of an agreement to bring Sosei Heptares’ cancer immunotherapy drug candidate into a first-in-human trial."

August 2022 "August 10, 2022 Cancer Research UK is working with global biopharma Sosei Heptares on a treatment they hope will bring immunotherapy benefits to new cancer types. Cancer Research UK, a charity dedicated to funding lifesaving oncology research, spent £388 million on cancer research last fiscal year. Much of that funding is distributed to support third party research, but the group also does its own

September 2022 "T cells are master regulators of the immune response tuning, among others, B cells, macrophages and NK cells. To exert their functions requiring high sensibility and specificity, T cells need to integrate different stimuli from the surrounding microenvironment. A finely tuned signalling compartmentalization orchestrated in dynamic platforms is an essential requirement for the proper and efficient response of these cells to distinct triggers. During years, several studies have depicted the pivotal role of the cytoskeleton and lipid microdomains in controlling signalling compartmentalization during T cell activation and functions. Here, we discuss mechanisms responsible for signalling amplification and compartmentalization in T cell activation, focusing on the role of CD28, chemokine receptors and the actin cytoskeleton. We also take into account the detrimental effect of mutations carried by distinct signalling proteins giving rise to syndromes characterized by defects in T cell functionality." Read more at the source #DrGPCR #GPCR #IndustryNews

Michel Bouvier "Michel Bouvier is a professor of Biochemistry and Molecular Medicine and the CEO of the Institute for Research in Immunology and Cancer ( IRIC ) at the Université de Montréal. In 1989, he returned to Montréal as a professor of biochemistry and a scholar of the Medical Research Since 2001, he holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology. He has supervised the research work of 75 graduate students and 40 post-doctoral fellows.

Michel Bouvier Michel Bouvier is a professor of Biochemistry and Molecular Medicine and the CEO of the Institute for Research in Immunology and Cancer ( IRIC ) at the Université de Montréal. In 1989, he returned to Montréal as a professor of biochemistry and a scholar of the Medical Research Since 2001, he holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology. He has supervised the research work of 75 graduate students and 40 post-doctoral fellows.

Michel Bouvier Michel Bouvier is a professor of Biochemistry and Molecular Medicine and the CEO of the Institute for Research in Immunology and Cancer ( IRIC ) at the Université de Montréal. In 1989, he returned to Montréal as a professor of biochemistry and a scholar of the Medical Research Since 2001, he holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology. He has supervised the research work of 75 graduate students and 40 post-doctoral fellows.